| [1] |
Tommy Nyberg, Debra Frost, Daniel Barrowdale, et al. Prostate cancer risks for male brca1 and brca2 mutation carriers: a prospective cohort study[J]. Eur Urol, 2020, 77(1): 24-35.
|
| [2] |
Elizabeth C Page, Elizabeth K Bancroft, Mark N Brook, et al. Interim results from the impact study: evidence for prostate-specific antigen screening in brca2 mutation carriers[J]. 2019, 76(6): 831-842.
|
| [3] |
郑琛琛, 周祥福. 2019版欧洲泌尿外科前列腺癌指南更新要点解读[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2019, 13(6): 361-364.
|
| [4] |
Hui W, Ting X, Xiao W, et al. Diagnostic performance of 68gallium labelled prostate-specific membrane antigen positron emission tomography/computed tomography and magnetic resonance imaging for staging the prostate cancer with intermediate or high risk prior to radical prostatectomy:a systematic review and meta-analysis[J]. World J Mens Health, 2020, 38(2): 208-219.
|
| [5] |
周祥福. 2018版欧洲泌尿外科前列腺癌指南更新要点解读[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2018, 12(5): 289-294.
|
| [6] |
Maha Hussain, Karim Fizazi, Fred Saad, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer[J]. N Engl J Med, 2018, 378(26): 2465-2474.
|
| [7] |
Karim Fizazi, Neal Shore, Teuvo L Tammela, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer[J]. N Engl J Med, 2019, 380(13): 1235-1246.
|
| [8] |
Frank Kunath, Katrin Jensen, Mariona Pinart, et al. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer[J]. Cochrane Database Syst Rev, 2019, 6(6): CD003506.
|
| [9] |
Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the stampede trial[J]. Ann Oncol, 2019, 30(12): 1992-2003.
|
| [10] |
Larysa HM Rydzewska, Sarah Burdett, Claire L Vale, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis[J]. Eur J Cancer, 2017, 84: 88-101.
|
| [11] |
Kim N Chi, Neeraj Agarwal, Anders Bjartell, et al. Apalutamide for metastatic, castration-sensitive prostate cancer[J]. N Engl J Med, 2019, 381(1): 13-24.
|
| [12] |
Ian D Davis, Andrew J Martin, Martin R Stockler, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer[J]. N Engl J Med, 2019, 381(2): 121-131.
|
| [13] |
Matthew R Smith, Fairooz Kabbinavar, Fred Saad, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer[J]. J Clin Oncol, 2005, 23(13): 2918-2925.
|
| [14] |
Hussain M, Wolf M, Marshall E, et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report[J]. J Clin Oncol, 1994, 12(9): 1868-1875.
|
| [15] |
Taylor CD, Elson P, Trump DL, et al. Importance of continued testicular suppression in hormone-refractory prostate cancer[J]. J Clin Oncol, 1993, 11(11): 2167-2172.
|
| [16] |
Giandomenico Roviello, Maria Rosa Cappelletti, Laura Zanotti, et al. Targeting the androgenic pathway in elderly patients with castrationresistant prostate cancer: A meta-analysis of randomized trials[J]. Medicine (Baltimore)，2016, 95(43): e4636.
|
| [17] |
Christopher P Evans, Celestia S Higano, Thomas Keane, et al. The prevail study: primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy-naive metastatic castration-resistant prostate cancer[J]. Eur Urol, 2016, 70(4): 675-683.
|
| [18] |
Andrew J Armstrong, Elizabeth Garrett-Mayer, Ronald de Wit, et al. Prediction of survival following first-line chemotherapy in men with castrationresistant metastatic prostate cancer[J]. Clin Cancer Res, 2016, 70(4): 675-683.
|
| [19] |
Howard I Scher, Michael J Morris, Walter M Stadler, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3[J]. J Clin Oncol, 2016, 34(12): 1402-1418.
|